Alan P. Lyss, MD

All articles by Alan P. Lyss, MD

Alan P. Lyss, MD

May 18, 2022

The 2-year overall survival rate was 32.5%.

Alan P. Lyss, MD

December 14, 2021

A meta-analysis revealed inferior responses, progression-free survival, and overall survival in patients exposed to antibiotics.

Alan P. Lyss, MD

October 29, 2021

Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.

Alan P. Lyss, MD

August 12, 2021

The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.

Next post in Practice Management